Z
3.66
-0.21 (-5.43%)
| Penutupan Terdahulu | 3.87 |
| Buka | 3.85 |
| Jumlah Dagangan | 990,021 |
| Purata Dagangan (3B) | 2,011,422 |
| Modal Pasaran | 260,542,048 |
| Harga / Jualan (P/S) | 7.13 |
| Harga / Buku (P/B) | 1.44 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 6 Aug 2026 |
| Margin Operasi (TTM) | -746.40% |
| EPS Cair (TTM) | -3.14 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 14.27% |
| Nisbah Semasa (MRQ) | 6.94 |
| Aliran Tunai Operasi (OCF TTM) | -151.52 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -79.27 M |
| Pulangan Atas Aset (ROA TTM) | -26.62% |
| Pulangan Atas Ekuiti (ROE TTM) | -59.45% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menaik | Bercampur |
| Biotechnology (Global) | Menaik | Bercampur | |
| Stok | Zentalis Pharmaceuticals, Inc. | Bercampur | Menurun |
AISkor Stockmoo
-0.8
| Konsensus Penganalisis | 2.0 |
| Aktiviti Orang Dalam | 1.5 |
| Volatiliti Harga | -4.5 |
| Purata Bergerak Teknikal | -2.5 |
| Osilator Teknikal | -0.5 |
| Purata | -0.80 |
|
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 13.58% |
| % Dimiliki oleh Institusi | 80.34% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Ishara Investments Lp | 31 Mar 2026 | 1,230,000 |
Tiada data dalam julat masa ini.
| Nama | Purata Belian ($) | Purata Jualan ($) | Jumlah Net | Jumlah Nilai Bersih ($) |
|---|---|---|---|---|
| JOHNSON DAVID MICHAEL | 3.52 | - | 57,100 | 200,992 |
| KARIUKI ENOCH | 3.52 | - | 57,100 | 200,992 |
| MYERS SCOTT DUNSETH | 3.52 | - | 57,100 | 200,992 |
| SKVARKA JAN | 3.52 | - | 57,100 | 200,992 |
| WALKER LUKE NATHANIEL | 3.52 | - | 57,100 | 200,992 |
| Jumlah Keseluruhan Kuantiti Bersih | 285,500 | |||
| Jumlah Keseluruhan Nilai Bersih ($) | 1,004,960 | |||
| Purata Pembelian Keseluruhan ($) | 3.52 | |||
| Purata Jualan Keseluruhan ($) | - | |||
| Nama | Pemegang | Tarikh | Jenis | Kuantiti | Harga | Nilai ($) |
|---|---|---|---|---|---|---|
| MYERS SCOTT DUNSETH | Pengarah | 16 Jun 2026 | Diperolehi (+) | 57,100 | 3.52 | 200,992 |
| KARIUKI ENOCH | Pengarah | 16 Jun 2026 | Diperolehi (+) | 57,100 | 3.52 | 200,992 |
| WALKER LUKE NATHANIEL | Pengarah | 16 Jun 2026 | Diperolehi (+) | 57,100 | 3.52 | 200,992 |
| SKVARKA JAN | Pengarah | 16 Jun 2026 | Diperolehi (+) | 57,100 | 3.52 | 200,992 |
| JOHNSON DAVID MICHAEL | Pengarah | 16 Jun 2026 | Diperolehi (+) | 57,100 | 3.52 | 200,992 |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |